Sernova (TSE:SVA) Shares Down 2.2% – Here’s Why

Sernova Corp. (TSE:SVA)’s stock price was down 2.2% during mid-day trading on Thursday . The stock traded as low as C$0.23 and last traded at C$0.23. Approximately 135,401 shares were traded during trading, a decline of 18% from the average daily volume of 164,533 shares. The stock had previously closed at C$0.23.

Analyst Ratings Changes

A number of research firms recently commented on SVA. Ventum Cap Mkts raised Sernova to a “strong-buy” rating in a report on Thursday, September 12th. Leede Financial dropped their target price on shares of Sernova from C$3.00 to C$1.50 and set a “speculative buy” rating for the company in a research report on Friday, September 13th. Finally, Ventum Financial cut their target price on shares of Sernova from C$3.00 to C$2.50 and set a “buy” rating for the company in a research note on Friday, September 13th.

Sernova Stock Down 2.2 %

The business has a 50-day moving average price of C$0.25 and a 200 day moving average price of C$0.28. The company has a current ratio of 0.32, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55. The stock has a market capitalization of C$73.20 million, a P/E ratio of -1.73 and a beta of 1.35.

Sernova (TSE:SVA) last released its quarterly earnings data on Monday, September 16th. The company reported C($0.02) EPS for the quarter, beating the consensus estimate of C($0.03) by C$0.01. On average, equities analysts expect that Sernova Corp. will post -0.08 EPS for the current fiscal year.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.